Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Antiviral Activity of MB-110 in Healthy Volunteers and HCV Patients
NCT02617615Phase 1Unknown
- Sponsor
- Microbio Co., Ltd.
- Start
- Dec 2017
- Primary completion
- Jun 2018
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatitis C (HCV) comparing MB-110 with Placebo (2 arms). Primary endpoints: Incidence of adverse events up to 19 days, Changes in vital signs from baseline up to 19 days and 11 more. Status: unknown.
02
Drugs
MB-110
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02617615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02617615.